Relapsed Or Refractory Marginal Zone Lymphoma Therapeutics
1. Ukoniq patent expiration
Treatment: Relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy; relapsed or refractory marginal z...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9969740 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(9 years from now) | |
| US10570142 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(7 years from now) | |
| US10414773 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(9 years from now) | |
| US9150579 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10072013 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(7 years from now) | |
| US10947244 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(9 years from now) | |
| US9669033 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(7 years from now) | |
| US10981919 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 05, 2026 |
| Orphan Drug Exclusivity(ODE-343) | Feb 05, 2028 |
| Orphan Drug Exclusivity(ODE-344) | Feb 05, 2028 |
Drugs and Companies using UMBRALISIB TOSYLATE ingredient
NCE-1 date: 05 February, 2025
Market Authorisation Date: 05 February, 2021
Dosage: TABLET
More Information on Dosage
UKONIQ family patents
